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Introduction
Lung cancer is the commonest cause of cancer-related death 
in men and women in Ireland, with 5-year average survival 
rate post-diagnosis of 17.9% (1). Electrolyte imbalance has 
been associated with poor survival in lung cancer patients 
(2-4). Hyponatremia and hypercalcemia are most commonly 
associated with lung cancer among other cancer types (5-7). 
Hyponatremia in lung cancer is most commonly related 
to the syndrome of inappropriate anti-diuretic hormone 
secretion (SIADH) (4,8-11). Paraneoplastic syndromes and 
bone metastasis are two main causes of lung cancer-related 
hypercalcemia (7,10,12). Prior reports suggest patients 
with hyponatremia and hypercalcemia are asymptomatic in 
early stages but can become symptomatic if untreated. This 
could affect treatment efficacy and decrease quality of life 
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(6,12-14). Early recognition and prompt correction of 
electrolyte imbalance may prevent clinical complications 
and potentially improve lung cancer morbidity and 
mortality (10,13). 
Our center, like other centers globally, is seeing a change 
in the demographics of patients presenting with lung 
cancer, including more females and more non-squamous 
tumours (1). Thus, there now is a paucity of information 
regarding the incidence of hyponatremia and hypercalcemia 
in lung cancer patients in Ireland, making it difficult to 
determine the extent to which the presence of electrolyte 
imbalance contributes to the high mortality rate of lung 
cancer. It is also unknown if correcting this electrolyte 
imbalance would be of prognostic significance in these 
patients. This study aimed to assess the incidence of 
hyponatremia and hypercalcemia in lung cancer patients in 
a local regional cancer centre, and further analyzed the role 
of such electrolyte imbalance in these patients by evaluating 
the associations with tumour histological subtype, ECOG-
PS and stage. 
Methods
Data source and study population
Ethical approval for this study was granted by the Clinical 
Research Ethics Committee of the Cork Teaching Hospitals 
[No. ECM6(b)5/12/17], in accordance with principles 
outlined in the Declaration of Helsinki for all human 
or animal experimental investigations. Data was derived 
from the National Cancer Control Programme (NCCP) 
Regional Cancer Centre (RCC) in Cork University 
Hospital (CUH) (15). Patients with tissue-proven lung 
cancer who were presented at our regional lung cancer 
MDT between January 2011 and December 2016 were 
retrospectively identified. This includes all patients with 
lung cancer presenting through our national healthcare 
service in Cork and Kerry. Patients were included if they 
had ≥1 post-cancer-diagnosis serum sodium and serum 
calcium laboratory test result available on the same day or 
week, and had no history of diagnosed hyponatremia (serum 
sodium ≤135 mEq/L) or hypercalcemia (serum calcium 
>2.62 mmol/L) (16), recorded >30 days prior to lung cancer 
diagnosis. Patients who were on diuretics or lithium were 
excluded. Our study population is representative of the age 
and sex distribution of the entire lung cancer population in 
Cork and Kerry. 
Study measures
Hyponatremia and hypercalcemia were defined according 
to the Common Terminology Criteria for Adverse Events 
(CTCAE) Grading Scale (16). Hyponatremia was defined as 
a serum sodium ≤135 mEq/L, and further classified as mild 
(130–135 mEq/L), moderate (125–129 mEq/L), or severe 
(<125 mEq/L). Cases of true hyponatremia were identified 
as serum osmolality <275 mOsm/kg within 48 hours of the 
serum sodium result with no evidence of hyperglycemia (9). 
Hypercalcemia was defined as serum calcium >2.62 mmol/L, 
and further classified as moderate (2.63–2.99 mmol/L), or 
severe (≥3.00 mmol/L). In cases of hypoalbuminemia (serum 
albumin <35 g/L), corrected serum calcium (CSC) was 
calculated as CSC (mmol/L) = 0.025 × (40 – serum albumin) 
+ serum calcium (17).
The classification of lung cancer was made in accordance 
with the American College of Chest Physicians (ACCP) 
guidelines (18). All lung cancer patients were histologically 
classified into three groups: (I) small cell lung carcinoma 
(SCLC); (II) NSCLC, which was further classified into 
NSCLC squamous and NSCLC non-squamous carcinoma; 
and (III) carcinoid carcinoma. The SCLC tumours were 
staged as limited (limited to one hemithorax, including 
mediastinal and supraclavicular lymphadenopathy) or 
extensive stage. Other lung tumours were staged using the 
TNM 7 classification (18). 
The following relevant patient clinical characteristics 
were recorded as of the date of cancer diagnosis: age 
of diagnosis, sex, smoking status, Eastern Cooperative 
Oncology Group Performance Status (ECOG-PS), lung 
function test results (FEV1, FVC, FEV1/FVC ratio, TLCO 
and DLCO), comorbidities, tumour subtype and stage. 
Statistical analysis
Categorical variables were reported as frequencies and 
percentages, while continuous variables were expressed 
as mean ± standard deviation (SD). Pearson’s Chi-Square 
test, Fisher’s Exact Test, One-way Analysis of Variance 
(ANOVA) or t-test were used where appropriate to assess 
the differences between groups with and without electrolyte 
imbalance. Spearman’s rho was used to measure the 
correlation between ordinal variables (ECOG-PS scores 
and severity of hyponatremia). All tests were two-tailed, 
with a significance level of P<0.05. All statistical analysis 
was performed using IBM SPSS, v24 software.
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Results
Patients
A total of 624 patients met all study requirements. 505 
(80.9%) patients had serum sodium and calcium values 
measured >30 days prior to time of diagnosis of lung cancer. 
Relevant characteristics of the study cohort recorded at time 
of diagnosis are shown in Table 1. Of 624 patients, there 
were 370 (59.3%) males and 254 (40.7%) females. The 
mean age at diagnosis was 67.4±10.0 years. The majority 
were current or former smokers at time of diagnosis (565 
patients, 90.5%). Diagnosis of lung cancer was made at an 
advanced stage (extensive stage in SCLC and stages IIIB/
IB in TNM staging) in 338 (54.2%) patients. The subtypes 
included were SCLC (102 patients), NSCLC squamous 
(222 patients), NSCLC non-squamous (282 patients) 
and carcinoid carcinoma (18 patients). There were no 
differences in gender, age at diagnosis, smoking status, lung 
function and co-morbidities between the hyponatremic and 
non-hyponatremic groups, or between the hypercalcemic 
and non-hypercalcemic groups. 
Incidence of hyponatremia
Hyponatremia was found in 197 (31.6%) patients 
(Table 1), of which: 151 (76.6%) were mild, 31 (15.7%) were 
moderate and 15 (7.6%) were severe hyponatremia (Table 2). 
The mean serum sodium of hyponatremic patients (n=197) 
was 131±4.5 mEq/L. The minimum serum sodium was 
108 mEq/L and the maximum value was 145 mEq/L.
Hyponatremic patients were stratified by histological 
subtype in Table 2. Hyponatremia was most common 
(P=0.001) in SCLC (42/102, 41.2%) compared to NSCLC 
squamous (81/222, 36.5%), NSCLC non-squamous 
(73/282, 25.9%), and carcinoid (1/18, 5.6%) subtypes 
(Table 2). Patients with SCLC (135±6.0 mEq/L) had 
significantly lower mean serum sodium values than patients 
with NSCLC non-squamous (137±3.9 mEq/L; P=0.001) 
and carcinoid (139±2.7 mEq/L; P=0.006) subtypes. The 
mean was also significantly lower in the NSCLC squamous 
(136±5.0 mEq/L) than NSCLC non-squamous subtype 
(P=0.008).
Hyponatremic and hypercalcemic cases were stratified 
by tumour stage in Table 3. Hyponatremia was identified in 
35/74 (47.3%) with extensive stage SCLC, and in 95/264 
(36.0%) with stages IIIB/IV (Table 3), both percentages 
significantly higher than in patients with early stages of lung 
cancer (P<0.041). The mean serum sodium for extensive 
stage SCLC (134±6.48 mEq/L) was significantly lower than 
for limited stage SCLC (137±3.56 mEq/L; P=0.003). The 
mean serum sodium was also significantly lower in Stage 
IIIB/IV cancer (136±4.52 mEq/L) than all other stages 
(138±4.22 mEq/L in stages I/II, and 137±3.90 mEq/L in 
stage IIIA; P<0.001).
Incidence of hypercalcemia
Hypercalcemia was found in 44 (7.1%) patients (Table 1), 
of which: 38 (86.4%) were moderate and 6 (13.6%) were 
severe hypercalcemia (Table 4). The mean serum calcium 
of hypercalcemic patients (n=44) was 2.79±0.20 mmol/L. 
The minimum serum calcium was 1.93 mmol/L and the 
maximum value was 3.47 mmol/L.
Hypercalcemic cases were stratified by histological 
subtype in Table 4. Hypercalcemia was most common 
(P=0.003) in NSCLC squamous (27/222, 12.2%) compared 
to SCLC (4/102, 3.92%), NSCLC non-squamous (12/282, 
4.26%), and carcinoid (1/18, 5.6%) subtypes (Table 4). 
The mean serum calcium values of patients with NSCLC 
squamous subtype (2.45±0.18 mmol/L) was significantly 
higher than in patients with SCLC (2.40±0.13 mmol/L; 
P=0.045) and NSCLC non-squamous (2.40±0.13 mmol/L; 
P=0.001) subtypes.
When stratified by tumour stage (Table 3), no patients 
with limited stage SCLC had hypercalcemia compared to 
4/74 (5.4%) patients with extensive stage SCLC tumours, 
but this difference was insignificant (P=0.573) (Table 1). For 
the TNM Classification, hypercalcemia was significantly 
more common (P=0.016) in stages IIIB/IV (24/264, 9.1%) 
and stage IIIA (9/67, 13.4%) than in early stage (7/191, 
3.7%) (Table 3). The mean serum calcium for extensive 
SCLC (2.42±0.13 mmol/L) was significantly higher than 
for limited SCLC (2.35±0.10 mmol/L; P=0.007). The mean 
serum calcium was also significantly higher in patients 
with stage IIIA (2.43±0.17 mmol/L) and IIIB/IV (2.44± 
0.17 mmol/L) compared to stages I/II (2.38±0.12 mmol/L; 
P<0.037). The difference in mean serum calcium of stages 
IIIA and IIIB/IV was insignificant (P=0.688). 
ECOG-PS
Patients with hyponatremia showed poorer ECOG-PS 
scores than those without hyponatremia (P=0.012) (Table 1). 
When stratified by stage, hyponatremia was associated with 
poorer ECOG-PS scores only at the early (stages I/II) stage 
of NSCLC (P=0.039) while the presence of hyponatremia 
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Table 2 Stratification of serum sodium according to histological subtype
Histological subtype
Serum sodium (mEq/L)
Total casesMild hyponatremia 
(130 to 135)








SCLC 30 5 7 42 60 102
NSCLC (squamous) 63 12 6 81 141 222
NSCLC (non-squamous) 57 14 2 73 209 282
Adenocarcinoma 56 14 2 72 200 272
Large cell carcinoma 1 0 0 1 9 10
Carcinoid 1 0 0 1 17 18
Total cases (%) (n=624) 151 (24.2) 31 (5.0) 15 (2.4) 197 (31.6) 427 (68.4) 624
Table 3 Severity of hyponatremia and hypercalcemia cases according to tumour stage
Staging [n]





















Limited stage [28] 6 1 0 7 (25.0) 0 0 0 (0)
Extensive stage [74] 24 4 7 35 (47.3) 4 0 4 (5.4)
TNM staging [522]
Stage I/II [191] 32 5 4 41 (21.5) 6 1 7 (3.7)
Stage IIIA [67] 16 3 0 19 (28.4) 8 1 9 (13.4)
Stage IIIB/IV [264] 73 18 4 95 (36.0) 20 4 24 (9.1)
Table 4 Stratification of corrected serum calcium (CSC) according to histological subtype
Histological subtype
Corrected serum calcium (mmol/L)










SCLC 4 0 4 98 0 102
NSCLC (squamous) 23 4 27 193 2 222
NSCLC (non-squamous) 10 2 12 269 1 282
Adenocarcinoma 10 2 12 259 1 272
Large cell carcinoma 0 0 0 10 0 10
Carcinoid 1 0 1 17 0 18
Total cases (%) (n=624) 38 (6.1) 6 (0.96) 44 (7.1) 577 (92.5) 3 (0.48) 624
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had no effect on ECOG-PS scores at the advanced (stages 
III/IV) stage of NSCLC (P=0.148), or at the limited and 
extensive stages of SCLC (P<0.562). The ECOG-PS score 
was positively correlated with severity of hyponatremia at 
the early stage of NSCLC (Spearman correlation coefficient 
=0.325; P=0.003). There was no difference in ECOG-PS 
scores of patients with and without hypercalcemia (P=0.333) 
(Table 1). Further comparison by stage was not possible due 
to the small number of hypercalcemic patients. 
Discussion
In this study, we demonstrated that (I) hyponatremia is a 
common occurrence at time of diagnosis of lung cancer 
while hypercalcemia is uncommon; (II) characteristics of 
lung cancer patients with hyponatremia or hypercalcemia 
differed significantly in subtype and stage from those 
without either electrolyte imbalance; and (III) ECOG-PS 
was positively correlated with severity of hyponatremia at 
the early stage of NSCLC.
The incidence of hyponatremia in our study was similar 
to reported incidence rates of 34.5% in Poland (4) and 
44.8% in India (11), that used the same serum sodium 
cutoff value measured at time of diagnosis of lung cancer. 
The incidence of hyponatremia was significantly highest 
in the SCLC subtype, and this was consistent with previous 
studies (8,19). This observation can be explained by the 
occurrence of paraneoplastic SIADH (4,8,10,11). SIADH is 
more common in SCLC, occurring in 15% of patients with 
SCLC compared to 0.7% of patients with NSCLC (20). 
Our study accounted for various causes of hyponatremia 
by excluding all patients with previously diagnosed 
hyponatremia, and known to be on diuretics. However, 119 
(19.1%) patients did not have serum sodium measurements 
>30 days before lung cancer diagnosis, of which 28 patients 
had hyponatremia at time of cancer diagnosis. It is possible 
that these patients could have had chronic hyponatremia. 
Anti-cancer therapies were not a contributing factor 
as measurements were recorded at time of diagnosis of 
lung cancer. In patients (n=21) with measurements of 
serum osmolality and urine osmolality available, all had 
serum osmolality <275 mOsm/kg, and urine osmolality 
>100 mOsm/kg. However, diagnosing SIADH requires 
further knowledge of the patient’s volume status and urinary 
sodium. Most previously published studies focus only on 
SCLC tumours (9,21), while studies on NSCLC attribute 
hyponatremia to anti-cancer therapies (6). However, our 
study shows pre-treatment hyponatremia is also common in 
the NSCLC subtypes, hence an NSCLC subtype-specific 
explanation should be explored.
The advanced stages of lung cancer were associated 
with lower mean serum sodium values than early stages. 
The incidence of hyponatremia was significantly highest 
in the advanced stages of lung cancer. This finding 
was consistent with previous studies (21,22). However, 
other studies, conducted on patients with SCLC, have 
reported hyponatremia occurs independently of stage 
(9,10). Hyponatremia in the advanced stage has been 
hypothesized to be caused by more severe paraneoplastic 
syndromes secondary to increased tumour burden, resulting 
in elevated ectopic hormone production (11,21,22). 
Further measurement of association between the onset of 
hyponatremia with the presence and number of metastatic 
sites could determine if hyponatremia would be useful as a 
measure of tumour burden or as a predictor of recurrence.
Unlike hyponatremia, lung cancer-related hypercalcemia 
has been less extensively studied. Our incidence of 
hypercalcemia was higher than the reported incidence rate 
of 4.32% in the United Kingdom (7) using the same cutoff 
values measured at time of diagnosis of lung cancer. This 
could be due to systematic differences in geographical 
location of our study population.
Consistent with previous studies (5,10), hypercalcemia 
occurred most commonly in the NSCLC squamous 
subtype, compared to the SCLC and NSCLC non-
squamous subtypes. This finding can be may be explained 
by ectopic parathyroid hormone-related protein (PTHrP) 
production by the NSCLC squamous tumour (2,7,10,12). 
In our study, it was not possible to confirm ectopic PTHrP 
production in these patients as PTH and PTHrP levels 
were not routinely measured. However, the statistically 
significant higher incidence of hypercalcemia in patients 
with NSCLC squamous subtype indicates a systematic 
difference exists between this group and patients with other 
histological subtypes. The occurrence of paraneoplastic 
syndromes would be the most likely explanation for this 
difference. Early recognition of hypercalcemia may allow 
for early diagnosis of paraneoplastic syndromes and 
contribute to detection of the tumour at an earlier, treatable 
stage.
Our study finding of significantly higher mean calcium 
values in the advanced stages of all subtypes of lung cancer 
than early stages is consistent with previous studies, 
which reported increased hypercalcemia incidence as lung 
cancer progresses to more advanced stages (2,3,7,12). 
Hypercalcemia in the advanced stage has been attributed 
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to the presence of bone metastasis, estimated to cause 20% 
of hypercalcemia of malignancy (2,12). Although the site 
of metastasis was not recorded, patients with advanced 
stage of lung cancer often have distant metastasis, and 
severe hypercalcemia in our study population presented 
mostly in stages IIIB/IV. Hence, the higher incidence of 
hypercalcemia could potentially be an indicator of tumour 
burden. Further measurement of the number of metastatic 
sites could confirm this hypothesis.
The mechanism of hypercalcemia in SCLC is still not 
understood beyond the rare occurrence of PTHrP and 
PTH-mediated hypercalcemia (23). In our study, although 
the extensive stage of SCLC showed higher mean calcium 
values than the limited stage, there was no difference in 
incidence of hypercalcemia between both stages. While 
this could mean hypercalcemia plays a less significant role 
in SCLC tumour burden than other subtypes, our study 
was limited by the small number of hypercalcemic SCLC 
patients. Nonetheless, as bone metastasis occurs in all 
histological subtypes, this finding indicates exploration of 
other reasons besides bone metastasis causing increased 
hypercalcemia incidence in advanced stages of NSCLC.
Another important f inding of our study is  that 
hyponatremic patients had statistically significantly poorer 
ECOG-PS scores than non-hyponatremic patients. This 
association was also reported in a prospective study of 116 
lung cancer patients (11). Performance status is a significant 
independent prognostic factor for survival in lung cancer 
(24,25). Poor ECOG-PS scores could be influenced by 
several factors such as advanced age, advanced clinical 
stage of lung cancer, smoking status and presence of 
comorbidities (26). Our study accounted for the clinical 
stage of lung cancer by comparing ECOG-PS scores with 
serum sodium status by stage. Hyponatremia significantly 
worsened the ECOG-PS of patients only in the early stage 
of NSCLC, whereas in advanced stages, hyponatremic 
pat ients  had the same ECOG-PS scores  as  non-
hyponatremic patients. This indicates that hyponatremia 
may be a potential prognostic factor in early stages, whereas 
poor ECOG-PS scores in advanced NSCLC is more likely 
due to increased tumour burden than low serum sodium. 
However, the retrospective methodology of our study 
may lead to unidentified confounders which can influence 
presumed associations.
Notably, hypercalcemic patients had the same ECOG-
PS scores as non-hypercalcemic patients. Hypercalcemia 
may not have been sufficiently severe to cause symptoms 
and influence their ECOG-PS scores. Our study was also 
limited by the small number of hypercalcemic patients. 
Further study of the association of severity of hypercalcemia 
with ECOG-PS scores would be worthwhile.
There are a number of study limitations principally 
related to our retrospective study design. Not all 
confounding factors may have been identified. 119 (19.1%) 
patients had no serum sodium and calcium measurement 
>30 days before lung cancer diagnosis, of which 28 patients 
had hyponatremia and 2 patients had hypercalcemia at 
time of diagnosis. It is possible that these patients may have 
unrecorded chronic hyponatremia or hypercalcemia. Not all 
patients on diuretics may have been identified and excluded. 
Unfortunately, we have no data on patient survival, but it 
would be interesting to determine the speed of onset and 
timeline of progression of electrolyte imbalance, which 
could influence the survival time of patients. 
Conclusions
In summary, we have shown for the first time the incidence 
of hyponatremia and hypercalcemia in a modern cohort 
of lung cancer patients in Ireland. Our results confirm 
hyponatremia is a common association in lung cancer, 
especially in SCLC. Hypercalcemia is an uncommon but 
significant association in the NSCLC squamous subtype. 
Hyponatremia might contribute to poorer ECOG-PS 
scores at early stage of NSCLC and should be further 
investigated.
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